Amgen Inc. (NASDAQ:AMGN) Shares Sold by Lynch & Associates IN

Lynch & Associates IN trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,154 shares of the medical research company’s stock after selling 171 shares during the period. Lynch & Associates IN’s holdings in Amgen were worth $1,343,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in Amgen during the third quarter valued at about $25,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the second quarter valued at approximately $30,000. Legacy Investment Solutions LLC purchased a new stake in Amgen during the third quarter worth approximately $29,000. Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter worth $36,000. Finally, Livelsberger Financial Advisory acquired a new position in shares of Amgen during the 3rd quarter valued at $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMGN. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. TD Cowen boosted their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Barclays increased their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. Bank of America reaffirmed an “underperform” rating and set a $256.00 target price on shares of Amgen in a research note on Tuesday, December 10th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.91.

Amgen Stock Down 0.7 %

Shares of AMGN traded down $1.98 on Friday, hitting $262.23. The company’s stock had a trading volume of 2,704,605 shares, compared to its average volume of 3,047,914. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market capitalization of $140.96 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 2.91 and a beta of 0.56. The firm’s fifty day moving average price is $280.24 and its 200-day moving average price is $309.15. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the firm earned $4.96 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post 19.53 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.63%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.